TScan Seeks 1-for-2 to 1-for-50 Reverse Split to Avoid Nasdaq Delisting
TCRX is trading near its 52-week low of $0.201 (15% above the low).
Summary
TScan Therapeutics is asking shareholders to approve a reverse stock split of 1-for-2 to 1-for-50 to regain Nasdaq's $1.00 minimum bid price compliance by February 23, 2027. The special meeting is November 20, 2026.
Key Events · Corporate Governance and Compliance · TCRX
-
Reverse Split Proposed to Cure Delisting
Board seeks approval for a reverse stock split of not less than 1-for-2 and not more than 1-for-50, with the exact ratio set by the board, to raise the share price above Nasdaq's $1.00 minimum bid.
-
Nasdaq Deficiency Deadline February 23, 2027
TScan received a Nasdaq deficiency letter on August 27, 2026 after 30 consecutive trading days below $1.00; it has until February 23, 2027 to regain compliance, with a possible transfer to the Nasdaq Capital Market for an additional 180 days.
-
Special Meeting Set for November 20, 2026
Shareholders of record as of October 16, 2026 will vote on the reverse split and an adjournment proposal; the board recommends approval of both.
-
Authorized Share Overhang Grows After Split
The split reduces outstanding shares without reducing the 610,000,000 authorized common shares, increasing authorized-but-unissued shares available for future issuance and dilution.
Analysis · TCRX · Life Sciences
TScan is asking shareholders to approve a reverse stock split of up to 1-for-50 to lift its $0.2379 share price back above Nasdaq's $1.00 minimum bid. The company has until February 23, 2027 to regain compliance, and failure would push the stock off the Nasdaq Global Market into over-the-counter trading. The split itself does not change any holder's percentage ownership, but it increases the number of authorized-but-unissued shares, giving the board room to issue equity without further shareholder votes — meaningful for a company that has already warned it may not survive as a going concern and is exploring financing. The vote is set for November 20, 2026.
How filings like this one have moved
In the 30 days to Oct 31, 2026, 40% of the 987 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.59%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, TCRX was trading at $0.23 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $15.7M. The 52-week trading range was $0.20 to $2.57. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.